Lipids & metabolic liver disease
Coronary artery disease risk prediction by combined stratification of low‐density lipoprotein‐cholesterol and high‐density lipoprotein‐cholesterol levels across different glucose statuses
Authors' conclusion
To prevent CAD, LDL-C levels should be strictly controlled in patients with low HDL-C levels regardless of glucose tolerance. Individualized treatment, which involves setting target LDL-C levels based on glucose tolerance and HDL-C values, is required.
Study context
- Population
- Individuals without a history of coronary artery disease (CAD) or familial hypercholesterolaemia, nationwide claims database, 2008–2019; normoglycaemia, borderline glycaemia and diabetes
- Participants
- 1,524,289 individuals
- Exposure
- Combined high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) levels by glucose status
- Outcome
- Incident CAD
- Follow-up
- Mean 5.5 years
Methodological detailsnationwide claims database
- Nationwide claims database
Main finding
As reported in the abstract
Each group vs HDL-C 60-99 mg/dL and LDL-C <80 mg/dLHazard ratio (95% CI)
HDL-C <40 mg/dL and LDL-C <80 mg/dL, normoglycaemia
2.74(1.47–5.11)
HDL-C <40 mg/dL and LDL-C <80 mg/dL, borderline glycaemia
2.52(1.30–4.91)
HDL-C <40 mg/dL and LDL-C <80 mg/dL, diabetes
2.85(1.68–4.84)
- Incident CAD events
- 8301 (0.99/1000 person-years)
- Least favourable (HDL-C <40 mg/dL, LDL-C 180-199 mg/dL) vs most favourable levels: increase in new-onset CAD risk in normoglycaemia, borderline glycaemia and diabetes, respectively
- 19-, nine- and seven-fold
Observational data: associations, not effects.
Original publication
Coronary artery disease risk prediction by combined stratification of low‐density lipoprotein‐cholesterol and high‐density lipoprotein‐cholesterol levels across different glucose statuses. Diabetes Obes Metab. Published 24 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →